Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia
Hemasphere
.
2025 Jan 15;9(1):e70067.
doi: 10.1002/hem3.70067.
eCollection 2025 Jan.
Authors
Christine E Ryan
1
,
Yue Ren
2
,
Svitlana Tyekucheva
2
3
,
Jon E Arnason
4
,
Adam M Boruchov
5
,
Caron A Jacobson
1
,
David C Fisher
1
,
Hari Miskin
6
,
Peter Sportelli
6
,
Jennifer R Brown
1
,
Matthew S Davids
1
Affiliations
1
Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA.
2
Department of Data Science Dana-Farber Cancer Institute Boston Massachusetts USA.
3
Department of Biostatistics Harvard TH Chan School of Public Health Boston Massachusetts USA.
4
Department of Medical Oncology Beth Israel Deaconess Medical Center Boston Massachusetts USA.
5
Cancer Institute, Nuvance Health Danbury Connecticut USA.
6
TG Therapeutics New York USA.
PMID:
39816532
PMCID:
PMC11733307
DOI:
10.1002/hem3.70067
No abstract available